Navigation Links
Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
Date:10/21/2008

Company Postpones Special Meeting of Shareholders until further notice

RICHMOND, Va., Oct. 21 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that on Thursday, October 16, 2008 NASDAQ issued a notice that:

-- Effective immediately, NASDAQ has suspended the enforcement of the rules

requiring a minimum $1.00 closing bid price.

-- Effective immediately, NASDAQ has also suspended the enforcement of the

rules requiring a minimum market value of publicly held shares (MVPHS).

-- NASDAQ will not take any action to delist any security for these

concerns during the suspension.

-- The suspension will remain in effect through Friday, January 16, 2009

and the original rules will be reinstated on Tuesday, January 20, 2009.

Prior to the suspension, Insmed had been given until December 15, 2008 to evidence a closing bid price of $1.00 or more for a minimum of 10 consecutive business days to remain listed on The NASDAQ Stock Market.

As a result of the rules suspension the Special Meeting of Shareholders, planned for November 24, 2008 to seek shareholder approval of a reverse split, should the Company need it, has been postponed until further notice.

Insmed will provide further information as it becomes available from NASDAQ.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, strategic alternatives, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that strategic alternatives may never be consummated, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow-on biologics market may be unsuccessful, we may be unable to secure an appropriate business partner for our follow-on biologics business, our common stock could be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Common Stock

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Insmed to Seek Shareholder Approval for Reverse Split
2. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
3. Insmed to Present at Biosimilars 2008 Conference
4. Insmed to Present at BioPharm Asia 2008 Conference
5. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
6. Insmed CEO to Present at Drug Discovery & Development Conference
7. Insmed to Host Second Quarter 2008 Conference Call
8. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
9. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
10. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
11. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)...   Instrument Business Outlook ( IBO ... ) the 2016 Company of the Year. ... tracking developments in the analytical and life science ... achieved outstanding technical, operational and financial results throughout ... IBO. "In 2016, Bio-Techne capitalized on opportunities in ...
(Date:1/23/2017)... 2017  Spherix Incorporated (Nasdaq: SPEX ) ... of technology and monetization of intellectual property, today provided ... Anthony Hayes , Chief Executive Officer of ... to communicate with shareholders about the status of existing ... on other patent assets that fit with our current ...
(Date:1/23/2017)... PA (PRWEB) , ... January 23, 2017 , ... ... Thomas has been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. ... of Madras in India. , Dr. Thomas’ career as an academic and ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific Inc, a ... ( http://www.gandlscientific.com ), has announced the opening of new offices in Cambridge, Massachusetts, ... and contractors. This is the latest step in G&L’s expansion of its global ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the leader ... technology, entered into a license and supply agreement with ... The agreement provides Singulex access to Thermo Scientific BRAHMS ... is used to diagnose systemic bacterial infection ... to aid in assessing the risk of ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral ... which grew to over 40 granted and pending patents. ... , , The Company,s ... " System, Device, and Method Estimating Force Applied to a Touch ... forego costly hardware components needed to estimate the force and pressure applied ...
Breaking Biology News(10 mins):